SM
LRMR icon

Sabby Management’s Larimar Therapeutics LRMR Stock Holding History

Sabby Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-12
Closed -$69K – 239
2017
Q1 		$69K Buy
+12
New +$596 ﹤0.01% 242
2016
Q4 		– Sell
-179
Closed -$15K – 314
2016
Q3 		$15K Buy
179
+101
+129% +$4.59K ﹤0.01% 307
2016
Q2 		$557K Sell
78
-43
-36% -$3.4K 0.03% 208
2016
Q1 		$966K Buy
121
+39
+48% +$3.08K 0.05% 157
2015
Q4 		$617K Buy
82
+2
+3% +$321 0.03% 222
2015
Q3 		$3.07M Buy
80
+71
+789% +$32K 0.13% 124
2015
Q2 		$381K Buy
+9
New +$3.77K 0.01% 268

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Sabby Management's LRMR Position: Q2 2017 in Review

Sabby Management sold out of Larimar Therapeutics (LRMR) in Q2 2017, closing a stake of 11,943 shares — an estimated $668K sold.

Sabby Management first reported a position in LRMR in Q3 2014 and held it in 4 quarters. The position peaked at $6.44M in Q3 2014. 69 funds tracked by Wall St. Rank hold LRMR as of Q2 2017.

  • Sabby Management reported no remaining Larimar Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Sabby Management sold 11,943 Larimar Therapeutics shares in Q2 2017, an estimated $668K.
  • Sabby Management first reported a position in Larimar Therapeutics in Q3 2014 and held it in 4 quarters.
  • Sabby Management's Larimar Therapeutics position peaked at $6.44M in Q3 2014.
  • 69 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2017.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.